FDA Approves Sparsentan as First-Ever Treatment for Focal Segmental Glomerulosclerosis

What Is Sparsentan and How Does It Treat FSGS?

Sparsentan, marketed under the brand name Filspari, represents a new class of therapy that simultaneously inhibits two receptor systems implicated in progressive kidney disease. By blocking the endothelin type A receptor and the angiotensin II type 1 receptor in a single molecule, sparsentan addresses both the hemodynamic and fibrotic mechanisms that contribute to glomerular injury and proteinuria in FSGS patients.

Focal segmental glomerulosclerosis is a condition characterized by scarring of the glomeruli — the kidney's filtering units — leading to progressive protein loss in the urine and eventual kidney failure. Until now, treatment has relied on off-label use of immunosuppressants and renin-angiotensin system blockers, none of which were specifically developed or approved for this indication. The FDA's decision marks a pivotal moment for the estimated tens of thousands of patients in the United States living with FSGS who previously had no approved targeted therapy.

What Evidence Supported the FDA Approval?

The pivotal DUPLEX study was a randomized, double-blind, active-controlled trial that compared sparsentan to the angiotensin receptor blocker irbesartan in patients with FSGS. The trial assessed reduction in proteinuria — a key marker of disease activity — as the primary endpoint. Sparsentan demonstrated a meaningful reduction in protein loss compared to the active control, supporting its dual mechanism of action as clinically beneficial in this population.

Sparsentan was initially granted accelerated approval by the FDA in 2023 for the treatment of IgA nephropathy, another rare kidney disease characterized by excessive proteinuria. The expansion to FSGS leverages the drug's established safety profile and its mechanism-based rationale for treating proteinuric kidney diseases more broadly. Common adverse effects observed in clinical trials included peripheral edema, dizziness, and hyperkalemia, consistent with the drug's pharmacological activity on endothelin and angiotensin pathways.

Why Is an Approved FSGS Treatment So Significant?

FSGS is one of the leading causes of nephrotic syndrome in adults and a significant driver of end-stage kidney disease requiring dialysis or transplantation. The disease can be primary (idiopathic), genetic, or secondary to other conditions, and its clinical course varies widely. For many patients, the disease progresses despite treatment with high-dose corticosteroids and calcineurin inhibitors, both of which carry substantial toxicity risks including diabetes, infections, and bone loss.

The approval of sparsentan provides clinicians with the first evidence-based, FDA-sanctioned treatment option specifically designed and tested in this patient population. Nephrologists and patient advocacy organizations, including the National Kidney Foundation, have highlighted the unmet need in FSGS for years. While sparsentan does not represent a cure, its ability to reduce proteinuria — a well-established surrogate marker for long-term kidney outcomes — offers meaningful hope for slowing disease progression and delaying the need for renal replacement therapy.